Sequence-based in silico analysis of well studied Hepatitis C Virus epitopes and their variants in other genotypes (particularly genotype 5a) against South African human leukocyte antigen backgrounds

BMC Immunology

Sheila M Bowyer¹  Adrian J Puren²  Nishi Prabdial-Sing² 

[1] Tshwane Academic Division, NHLS, Pretoria, South Africa;Division of Virology and Communicable Diseases Surveillance, School of Pathology, University of Witwatersrand, Johannesburg, South Africa

关键词: Epitope prediction;    HLA;    HCV;    Population coverage;    Viral variation;    Epitope vaccines;   

Others  :  1077859
DOI  :  10.1186/1471-2172-13-67

 received in 2012-06-25, accepted in 2012-11-30,  发布年份 2012

【 摘 要 】

Background

Host genetics influence the outcome of HCV disease. HCV is also highly mutable and escapes host immunity. HCV genotypes are geographically distributed and HCV subtypes have been shown to have distinct repertoires of HLA-restricted viral epitopes which explains the lack of cross protection across genotypes observed in some studies. Despite this, immune databases and putative epitope vaccines concentrate almost exclusively on HCV genotype 1 class I-epitopes restricted by the HLA-A*02 allele. While both genotype and allele predominate in developed countries, we hypothesise that HCV variation and population genetics will affect the efficacy of proposed epitope vaccines in South Africa. This in silico study investigates HCV viral variability within well-studied epitopes identified in genotype 1 and uses algorithms to predict the immunogenicity of their variants from other less studied genotypes and thus rate the most promising vaccine candidates for the South African population. Six class I- and seven class II- restricted epitope sequences within the core, NS3, NS4B and NS5B regions were compared across the six HCV genotypes using local genotype 5a sequence data together with global data. Common HLA alleles in the South African population are A30:01, A02:01, B58:02, B07:02; DRB1*13:01 and DRB1*03:01. Epitope binding to 13 class I- and 8 class –II alleles were described using web-based prediction servers, Immune Epitope Database, (IEDB) and Propred. Online population coverage tools were used to assess vaccine efficacy.

Results

Despite the homogeneity of genotype 1 and genotype 5 over the epitopes, there was limited promiscuity to local HLA-alleles.Host differences will make a putative vaccine less effective in South Africa. Of the 6 well-characterized class I- epitopes, only 2 class I- epitopes were promiscuous and 3 of the 7 class-II epitopes were better conserved and promiscuous. By fine tuning the putative vaccine using an optimal cocktail of genotype 1 and 5a epitopes and local HLA data, the coverage was raised from 65.85% to 91.87% in South African Blacks.

Conclusion

While in vivo and in vitro studies are needed to confirm immunogenic epitopes, in silico HCV epitope vaccine design which takes into account HCV variation and host allele frequency will maximize population coverage in different ethnic groups.

【 授权许可】

   
2012 Prabdial-Sing et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
• [2]Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796.
• [3]Schulze ZurWiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, Jones AM, Nolan BE, Kasprowicz V, McMahon C, Wurcel A, Lohse AW, Lewis-Ximenez LL, Chung RT, Kim AY, Allen TM, Walker BD, Longworth South Africa: Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood 2007, 110:1559-1569.
• [4]Klade CS, Kubitschke A, Stauber RE, Meyer MF, Zinke S, Wiegand J, Zauner W, Aslan N, Lehmann M, Cornberg M, Manns MP, Reisner P, Wedemeyer H: Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. Vaccine 2009, 27:3099-3108.
• [5]Bukh J: A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 2004, 39:1469-1475.
• [6]Ploss A, Rice CM: Towards a small animal model for hepatitis C. EMBO Rep 2009, 10:1220-1227.
• [7]Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A: A genetically humanized mouse model for hepatitis C virus infection. Nature 2011, 474:208-211.
• [8]Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM: HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
• [9]Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O'Gorman M, Beaman K, Cotler SJ, Hershow R, Rong L: Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009, 6:46. BioMed Central Full Text
• [10]Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J: Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 2008, 82:3438-3451.
• [11]Sarobe P, Lasarte JJ, Garcia N, Civeira MP, Borras-Cuesta F, Prieto J: Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. J Viral Hepat 2006, 13:47-55.
• [12]Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S: Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2010, 44:140-145.
• [13]Paximadis M, Mathebula TY, Gentle NL, Vardas E, Colvin M, Gray CM, Tiemessen CT, Puren A: Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and caucasian South African population. Hum Immunol 2012, 73:80-92.
• [14]Statistics South Africa. 2010. http://www.statssa.gov.za/PublicationsHTML/P03022010/html/P03022010.html webcite
• [15]Prabdial-Sing N, Puren AJ, Mahlangu J, Barrow P, Bowyer SM: Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol 2008, 153:2049-2058.
• [16]Rosen HR: Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011, 364(25):2429-2438.
• [17]New allele Frequency Database. 2003. http://www.allefrequencies.net webcite
• [18]MacNamara A, Kadolsky U, Bangham CR, Asquith B: T-cell epitope prediction: rescaling can mask biological variation between MHC molecules. PLoS Comput Biol 2009, 5(3):e1000327.
• [19]Lin HH, Zhang GL, Tongchusak S, Reinherz EL, Brusic V: Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research. BMC Bioinformatics 2008, 9(12):S22. BioMed Central Full Text
• [20]Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR: Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003, 37:577-589.
• [21]Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS: Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009, 27:5142-5151.
• [22]Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, Lu X, Zhang H, Xu ZK: A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen. Arch Virol 2008, 153:1021-1029.
• [23]Memarnejadian A, Roohvand F, Arashkia A, Rafati S, Shokrgozar MA: Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept Lett 2009, 16:842-850.
• [24]Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M, Chisari FV: Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995, 95:521-530.
• [25]Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspe G, Fournillier A: A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008, 26:2471-2481.
• [26]Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, Valli A, Fiaccadori F, Ferrari C: Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999, 30:1088-1098.
• [27]Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD: Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002, 76:12584-12595.
• [28]Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR: Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997, 71:6011-6019.
• [29]Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, Allen TM, McGovern B, Lewis-Ximenez L, Sidney J, Sette A, Chung RT, Walker BD: Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005, 175:3603-3613.
• [30]Sidney J, Peters B, Frahm N, Brander C, Sette A: HLA class I supertypes: a revised and updated classification. BMC Immunol 2008, 9:1. BioMed Central Full Text
• [31]Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, Fevery J, Delport W, Van der Merwe S, Van Ranst M: Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 2006, 80:4220-4226.
• [32]Henquell C, Cartau C, Abergel A, Laurichesse H, Regagnon C, De Champs C, Bailly JL, Peigue-Lafeuille H: High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J Clin Microbiol 2004, 42:3030-3035.
• [33]Noppornpanth S, Poovorawan Y, Lien TX, Smits SL, Osterhaus AD, Haagmans BL: Complete genome analysis of hepatitis C virus subtypes 6t and 6u. J Gen Virol 2008, 89:1276-1281.
• [34]Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, et al.: Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140.
• [35]Accapezzato D, Fravolini F, Casciaro MA, Paroli M: Hepatitis C flare due to superinfection by genotype 4 in an HCV genotype 1b chronic carrier. Eur J Gastroenterol Hepatol 2002, 14:879-881.
• [36]Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, et al.: Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology 2009, 50:1017-1029.
• [37]Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H: Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 2008, 26:3818-3826.
• [38]Tong JC, Tan TW, Ranganathan S: Methods and protocols for prediction of immunogenic epitopes. Brief Bioinform 2007, 8:96-108.
• [39]Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
• [40]Lundegaard C, Lund O, Buus S, Nielsen M: Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 2010, 130(3):309-318.
• [41]Donnes P, Elofsson A: Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 2002, 3:25. BioMed Central Full Text
• [42]Stranzl T, Larsen MV, Lundegaard C, Nielsen M: NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010, 62(6):357-368.
• [43]McNamara LA, He Y, Yang Z: Using epitope predictions to evaluate efficacy and population coverage of the Mtb72f vaccine for tuberculosis. BMC Immunol 2010, 11:18. BioMed Central Full Text
• [44]Shehzadi A, Ur Rehman S, Idrees M: Promiscuous prediction and conservancy analysis of CTL binding epitopes of HCV 3a viral proteome from Punjab Pakistan: an in silico approach. Virol J 2011, 8:55. BioMed Central Full Text
• [45]Rai J, Lok KI, Mok CY, Mann H, Noor M, Patel P, Flower DR: Immunoinformatic evaluation of multiple epitope ensembles as vaccine candidates: E coli 536. Bioinformation 2012, 8(6):272-275.
• [46]Dimitrov I, Flower D, Doytchinova I: Improving in silico prediction of epitope vaccine candidates by union and intersection of single predictors. World Journal of Vaccines 2011, 1(2):15-22.
• [47]Ribeiro SP, Rosa DS, Fonseca SG, Mairena EC, Postol E, Oliveira SC, Guilherme L, Kalil J, Cunha-Neto E: A vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II molecules. PLoS One 2010, 5(6):e11072.
• [48]Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson KL, Schulze Zur Wiesch J, et al.: Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011, 140(2):686-696. e681
• [49]Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, et al.: Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 2011, 60(11):1563-1571.
• [50]Neumann-Haefelin C, Kuntzen T, Schmidt KN, Sidney J, Caillet-Saguy C, Binder M, Kersting MWK, Power KA, Ingber S, Reyor LL, Hills-Evans AYK, Lauer GM, Lohmann V, Sette A, Henn MR, Thimme R, Allen TM: HLA-B27 selects for rare escape mutations that SignificantlyImpair Hepatitis C Virus replication and require compensatory mutations. Hepatology 2011, 54(4):1157-1166.
• [51]Bowyer S: Molecular characterization of the hepatitis B virus is South Africa. PhD thesis. Johannesburg: University of the Witwatersrand, Department of Virology; 2002.
• [52]Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, Grey HM, Kubo RT: Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 1994, 31:813-822.
• [53]Lang KA, Yan J, Draghia-Akli R, Khan A, Weiner DB: Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008, 26:6225-6231.
• [54]Shin IT, Tanaka Y, Tateno Y, Mizokami M: Development and public release of a comprehensive hepatitis virus database. Hepatol Res 2008, 38:234-243.
• [55]Hall T: BioEdit. 1997. http://www.mbio.ncsu.edu webcite
• [56]Choo QL, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, Coit D, Medina-Selby R, Barr PJ, et al.: Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991, 88:2451-2455.
• [57]Crooks GE, Hon G, Chandonia JM, Brenner SE: WebLogo: a sequence logo generator. Genome Res 2004, 14:1188-1190.
• [58]Immune Epitope Database (IEDB) version 2.0. 2010. http://tools.immuneepitope.org/main/jsp/menu.jsp webcite
• [59]ProPred II. 2001. http://www.imtech.res.in/raghava/propred/index.html webcite
• [60]Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, Salimi N, Damle R, Sette A, Peters B: The immune epitope database 2.0. Nucleic Acids Res 2010, 38:D854-62.
• [61]Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O: Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003, 12:1007-1017.
• [62]ProPred I. 2003. http://www.imtech.res.in/raghava/propredI/index.html webcite
• [63]Singh H, Raghava GP: ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001, 17:1236-1237.
• [64]Toussaint NC, Kohlbacher O: OptiTope–a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res 2009, 37:W617-W622.